Home Sitemap Contact us Accessibility Statement Top of the page
  • Actiq® (Fentanyl citrate) from Teva

    Actiq®

    (oral transmucosal fentanyl citrate)

Prescribing Actiq®

Actiq® (oral transmucosal fentanyl citrate) compressed lozenge with integral oromucosal applicator1

Therapeutic Indications

Actiq® is indicated for the management of breakthrough pain in patients already receiving maintenance opioid therapy for chronic cancer pain. Breakthrough pain is a transitory exacerbation of pain that occurs on a background of otherwise controlled persistent pain.1

Patients receiving maintenance opioid therapy are those who are taking at least 60mg of oral morphine daily, at least 25mcg of transdermal fentanyl per hour, at least 30mg of oxycodone daily, at least 8mg of oral hydromorphone daily or an equianalgesic dose of another opioid for a week or longer.1

Facts about Actiq®

Rapid absorption through the buccal mucosa.1

Plasma fentanyl concentrations higher and more rapidly attained than those following oral solution administration.2

Peak plasma concentrations obtained in 22 minutes (2.5) for Actiq® compared to 101 minutes (48.8) for oral fentanyl solution (p=0.003).2

About Actiq®

Pain for healthcare professionals

One Actiq® lozenge contains 200mcg / 400mcg / 600mcg / 800mcg / 1200mcg / 1600mcg fentanyl (as citrate).1

Excipient(s): Each Actiq® lozenge contains dextrates (equivalent to approximately 2g of glucose), sucrose (approximately 30mg confectioner’s sugar) and propylene glycol (part of the artificial berry flavour and imprinting ink) as excipients.1

For a full list of excipients, see Section 6.1. of the Summary of Product Characteristics.1

Marketing Authorisation

Teva Pharma B.V.
Swensweg 5
2031 GA Haarlem
The Netherlands

Marketing Authorisation Number(s)

  • PL 14776/0092 - 0097

Resources for Actiq®

You can ask a question, request to see a representative from Teva, or report a side effect.

Ask a Question Request a Rep Report Suspected Side Effect
Medicine supporting documentation for Actiq®
  • Summary of Product Characteristics - Actiq® (Fentanyl citrate) 200 mcg
    View Document >
  • Summary of Product Characteristics - Actiq® (Fentanyl citrate) 400 mcg
    View Document >
  • Summary of Product Characteristics - Actiq® (Fentanyl citrate) 600 mcg
    View Document >
  • Summary of Product Characteristics - Actiq® (Fentanyl citrate) 800 mcg
    View Document >
  • Summary of Product Characteristics - Actiq® (Fentanyl citrate) 1200 mcg
    View Document >
  • Summary of Product Characteristics - Actiq® (Fentanyl citrate) 1600 mcg
    View Document >
  • Package Leaflet: Information for the user - Actiq® (Fentanyl citrate) 200 / 400 / 600 / 800 /1200 / 1600 mcg
    View Document >

1 Actiq® (Fentanyl citrate) - Summary of Product Characteristics

2 Streisand JB, Varvel JR, Stanski DR et al. Absorption and bioavailablility of oral transmucosal fentanyl citrate. Anesthesiology 1991; 75:223-229

Teva UK Limited

Are you a healthcare professional?

To access this section of the Teva UK Limited website you need to be a member of the healthcare profession because the materials included in this area of our website are specifically prepared for that audience only.
To understand why that is - please visit: Working in a regulated environment

Please click on the appropriate button below to confirm that you are healthcare professional.
If you are not a healthcare professional, you will be taken to an area of the website that is appropriate for you.

I am a